IDEXX Laboratories (IDXX) is a publicly traded Healthcare sector company. As of July 5, 2026, IDXX trades at $557.80 with a market cap of $44.00B and a P/E ratio of 40.74. IDXX moved +4.06% today. Year to date, IDXX is -18.25%; over the trailing twelve months it is +2.78%. Its 52-week range spans $356.14 to $769.98. Analyst consensus is buy with an average price target of $703.67. Rallies surfaces IDXX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
IDEXX Adds Taeniid Tapeworm Detection to Fecal Dx Antigen Platform with No Extra Cost: IDEXX has added detection of Taenia and Echinococcus taeniid tapeworm species to its Fecal Dx antigen testing platform, expanding clinical scope to seven parasite groups. Starting late June, U.S. and Canadian reference lab customers will automatically receive the enhanced panels at no additional cost.
| Metric | Value |
|---|---|
| Price | $557.80 |
| Market Cap | $44.00B |
| P/E Ratio | 40.74 |
| EPS | $13.69 |
| Dividend Yield | 0.00% |
| 52-Week High | $769.98 |
| 52-Week Low | $356.14 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $4.45B |
| Net Income | $1.10B |
| Gross Margin | 62.05% |
7 analysts cover IDXX: 0 strong buy, 4 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $703.67.